Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net loss	$ (24,522,821)	$ (4,811,187)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,127	6,020
Stock and stock option compensation and deferred consulting	2,620,547	1,121,269
Inducement of warrant exchange		170,616
Amortization of discounts and financing fees	13,333	342,230
Change in fair value of derivative liabilities	(723,712)	2,630,024
Dividend series A convertible preferred stock	231,632
Unrealized other comprehensive loss	321
Loss on impairmaent of goodwill	21,633,882
Changes in operating assets and liabilities:
Inventory		86,490
Accounts receivable	(213)	(215,943)
Accounts receivable from related parties	(6,115)
Prepaid expenses and other assets	(13,737)	(73,902)
Accounts payable and accrued expenses	(215,491)	(56,511)
Net cash used in operating activities	(981,247)	(800,894)
Investing activities:
Purchase of fixed assets	(1,517)
Purchase of intellectual property	(3,630)	(15,100)
Net cash used in investing activities	(5,147)	(15,100)
Financing activities:
Proceeds from Series B convertible preferred stock	1,600,000
(Repayment of) proceeds from Loan	(20,000)	835,000
Proceeds from warrant exercise		14,691
Net cash provided by financing activities	1,580,000	849,691
Net increase in cash and cash equivalents	593,606	33,697
Cash and cash equivalents, beginning of period	86,396	29,430
Cash and cash equivalents, end of period	680,002	63,127
Non-cash investing and financing activities:
Common stock issued in merger	10,790,367
Beneficial conversion features on Series B convertible preferred stock	146,667
Net assets acquired in merger	74,681
Transfers from derivative liability to additional paid in capital		$ 3,098,548
Series C Preferred [Member]
Non-cash investing and financing activities:
Series C Convertible Preferred stock issued in merger	281,000